Literature DB >> 23244816

Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.

Paul Tappenden1, Jim Chilcott, Alan Brennan, Hazel Squires, Matthew Stevenson.   

Abstract

OBJECTIVES: This article presents a methodological framework for developing health economic models of whole systems of disease and treatment pathways to inform decisions concerning resource allocation-an approach referred to as "Whole Disease Modeling." This system-level approach can provide a consistent mathematical infrastructure for the economic evaluation of virtually any intervention across a disease pathway.
METHODS: The framework has been developed for cancer but is broadly generalizable to other diseases. It has been informed by pilot work, a systematic review of economic analyses, a qualitative examination of model development processes, and other literature from the fields of operational research, statistics, and health economics.
RESULTS: The framework is built on three principles: 1) the model boundary and breadth should capture all relevant aspects of the disease and its treatment-from preclinical disease through to death, 2) the model should be developed such that the decision node is conceptually transferable across the model, and 3) the costs and consequences of service elements should be structurally related. A generalized process for developing Whole Disease Models is presented. DISCUSSION: Although this approach involves a nontrivial investment of time and resource, its value may be realized when 1) multiple options for service change require economic analysis at a single time point, 2) a disease service changes rapidly and the model can be reused, 3) current services within a pathway have not been subjected to economic analysis, 4) upstream events are expected to have important downstream effects, or 5) simple cost-utility decision rules fail to reflect the complexity of the decision-makers' objectives.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23244816     DOI: 10.1016/j.jval.2012.07.008

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  10 in total

1.  Four Aspects Affecting Health Economic Decision Models and Their Validation.

Authors:  Talitha Feenstra; Isaac Corro-Ramos; Dominique Hamerlijnck; George van Voorn; Salah Ghabri
Journal:  Pharmacoeconomics       Date:  2021-12-16       Impact factor: 4.981

2.  Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community.

Authors:  Jonathan Tosh; Ben Kearns; Alan Brennan; Glenys Parry; Thomas Ricketts; David Saxon; Alexis Kilgarriff-Foster; Anna Thake; Eleni Chambers; Rebecca Hutten
Journal:  BMC Health Serv Res       Date:  2013-04-26       Impact factor: 2.655

Review 3.  How methodological frameworks are being developed: evidence from a scoping review.

Authors:  Nicola McMeekin; Olivia Wu; Evi Germeni; Andrew Briggs
Journal:  BMC Med Res Methodol       Date:  2020-06-30       Impact factor: 4.615

4.  Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology.

Authors:  Graeme Ball; Mitch Levine; Lehana Thabane; Jean-Eric Tarride
Journal:  Pharmacoecon Open       Date:  2021-04-24

5.  Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research.

Authors:  Thomas Patton; Paul Revill; Mark Sculpher; Annick Borquez
Journal:  Subst Use Misuse       Date:  2022-02-14       Impact factor: 2.164

6.  Discrete Event Simulation Model for Cost-Effectiveness Evaluation of Screening for Asymptomatic Patients with Lower Extremity Arterial Disease.

Authors:  Vojtěch Kamenský; Vladimír Rogalewicz; Ondřej Gajdoš; Gleb Donin
Journal:  Int J Environ Res Public Health       Date:  2022-09-19       Impact factor: 4.614

7.  Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer.

Authors:  Alessandra Buja; Giulia Pasello; Marco Schiavon; Giuseppe De Luca; Michele Rivera; Claudia Cozzolino; Anna De Polo; Manuela Scioni; Alberto Bortolami; Vincenzo Baldo; PierFranco Conte
Journal:  Thorac Cancer       Date:  2022-08-15       Impact factor: 3.223

8.  The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal.

Authors:  Emma McManus; Tracey Sach; Nick Levell
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

9.  Squaring the circle: a priority-setting method for evidence-based service development, reconciling research with multiple stakeholder views.

Authors:  Rebecca Hutten; Glenys D Parry; Thomas Ricketts; Jo Cooke
Journal:  BMC Health Serv Res       Date:  2015-08-12       Impact factor: 2.655

10.  Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.

Authors:  Alessandra Buja; Michele Rivera; Anna De Polo; Eugenio di Brino; Marco Marchetti; Manuela Scioni; Giulia Pasello; Alberto Bortolami; Vincenzo Rebba; Marco Schiavon; Fiorella Calabrese; Giovanni Mandoliti; Vincenzo Baldo; PierFranco Conte
Journal:  Thorac Cancer       Date:  2020-11-21       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.